Concomitant medications are emerging as a modifiable prognostic factor for immune checkpoint inhibitor treatment outcomes. This Review by Stone et al. highlights the potential immunomodulatory interactions of commonly prescribed medications and supplements, and proposes strategies to make better use of this information to guide clinical care.

Key Points. The endothelial glycocalyx component hyaluronan regulates PAR-agonist induced platelet activation through the C-type lectin layilinReduced Layi